Cat. No. 2992
Alternative Name: CGP 41251
Chemical Name: [9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide
Biological ActivityBroad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Fabbro et al (2000) PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 15 17. PMID: 10888033.
Tenzer et al (2001) The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. 61 8203. PMID: 11719451.
Nakazono-Kusaba et al (2004) PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts. Eur.J.Pharmacol. 497 155. PMID: 15306200.
If you know of a relevant citation for this product please let us know.
Keywords: PKC 412, supplier, Broad, spectrum, protein, kinases, inhibitors, conventional, PKC, PKC412, CGP41251
Find multiple products by catalog number
New Products in this Area
Potent MSK1 inhibitor; also inhibits other AGC group kinasesLH 846
Selective casein kinase 1δ inhibitorPPY A
Potent inhibitor of Abl T315l mutant and wild-type Abl kinasesFlavopiridol hydrochloride
Cyclin-dependent kinase inhibitorGSK2578215A
Potent, selective LRRK2 inhibitor; brain penetrantAmlexanox
Inhibitor of TBK1 and IKKε; antiallergic agentPF 05212384
Potent and selective dual PI 3-kinase/mTOR inhibitorPF 03814735
Aurora kinase A and B inhibitorPF 04691502
Dual PI 3-K/mTOR inhibitorTNP
Inhibitor of IP6K; also inhibits IP3KACHP
Selective IKKα and IKKβ inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantCZC 24832
Selective inhibitor of PI 3-Kinase γLY 333531 hydrochloride
Protein kinase C inhibitor; selective for β isozymesPF 06465469
Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK10Z-Hymenialdisine
Pan kinase inhibitor; potently inhibits MEK-1CP 690550 citrate
Potent JAK inhibitorWYE 687 dihydrochloride
Potent and selective mTOR inhibitor
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.